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Abstract
Background: In high tuberculosis (TB) burden settings, there is growing evidence that TB is common in children
with pneumonia, the leading cause of death in children under 5 years worldwide. The current WHO standard of
care (SOC) for young children with pneumonia considers a diagnosis of TB only if the child has a history of
prolonged symptoms or fails to respond to antibiotic treatments. As a result, many children with TB-associated
severe pneumonia are currently missed or diagnosed too late. We therefore propose a diagnostic trial to assess the
impact on mortality of adding the systematic early detection of TB using Xpert MTB/RIF Ultra (Ultra) performed on
nasopharyngeal aspirates (NPA) and stool samples to the WHO SOC for children with severe pneumonia, followed
by immediate initiation of anti-TB treatment in children testing positive on any of the samples.
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Methods: TB-Speed Pneumonia is a pragmatic stepped-wedge cluster randomized controlled trial conducted in six
countries with high TB incidence rate (Côte d’Ivoire, Cameroon, Uganda, Mozambique, Zambia and Cambodia). We
will enrol 3780 children under 5 years presenting with WHO-defined severe pneumonia across 15 hospitals over 18
months. All hospitals will start managing children using the WHO SOC for severe pneumonia; one hospital will be
randomly selected to switch to the intervention every 5 weeks. The intervention consists of the WHO SOC plus
rapid TB detection on the day of admission using Ultra performed on 1 nasopharyngeal aspirate and 1 stool
sample. All children will be followed for 3 months, with systematic trial visits at day 3, discharge, 2 weeks post-
discharge, and week 12. The primary endpoint is all-cause mortality 12 weeks after inclusion. Qualitative and health
economic evaluations are embedded in the trial.
Discussion: In addition to testing the main hypothesis that molecular detection and early treatment will reduce TB
mortality in children, the strength of such pragmatic research is that it provides some evidence regarding the
feasibility of the intervention as part of routine care. Should this intervention be successful, safe and well tolerated,
it could be systematically implemented at district hospital level where children with severe pneumonia are referred.
Trial registration: ClinicalTrials.gov, NCT03831906. Registered 6 February 2019.
Keywords: Children, Pneumonia, Tuberculosis, Nasopharyngeal aspirate, Stool, Xpert MTB/RIF ultra
Background
The World Health Organization (WHO) estimated that
1.12 million children (< 15 years) developed tuberculosis
(TB) in 2018, representing 11% of the overall TB case
load. WHO also estimated 205,000 child TB deaths that
year [1], making TB a top ten cause of death in children
under five years worldwide [2]. Recent modelling sug-
gests that almost all children dying from TB (96%) are
untreated and that 80% are aged below five years, with
treatment not started likely due to not being diagnosed
with TB [2]. Indeed, only 512,000 paediatric TB cases
were notified to WHO in 2018, representing a treatment
coverage of approximately 46% [1]. Childhood TB there-
fore remains undiagnosed and underreported, mostly
due to the challenges in confirming its diagnosis. This in
turn is largely because of the paucibacillary nature of
disease, and the difficulty in obtaining respiratory sam-
ples from young children [3].
Pneumonia is the leading cause of death in children
under the age of five years worldwide. There were an es-
timated 120 million pneumonia episodes in children
younger than 5 years in 2011, including 14 million severe
episodes [4], of which 1.3 million led to death. In 2014,
WHO revised its definitions for pneumonia and severe
pneumonia, the latter only justifying referral from pri-
mary health centres to higher level facilities for inpatient
treatment [5]. However, there are no global estimates of
mortality specifically attributable to severe pneumonia as
currently defined by WHO. Studies in children hospital-
ized with severe pneumonia conducted in East and East-
central Africa showed an inpatient mortality ranging
from 8.7 to 32% [6–8]. Children yet remain at high risk
for death even after discharge, notably during the first 3
months, with severe acute malnutrition an important
factor of poor outcome [6].
In high TB burden settings, there is growing evidence
that TB is common in children with pneumonia [9]. Al-
though TB is a chronic disease in adults, recent data
shows that the duration of respiratory symptoms before
admission can be acute in children with severe pneumo-
nia associated with TB [10]. A systematic review showed
that up to 23% of children admitted to hospital with an
initial diagnosis of pneumonia were later diagnosed with
TB [10, 11]. This is particularly true in the African and
South-East Asian WHO regions, which accounted for 30
and 40% of all paediatric TB cases in 2019 respectively
[1]. In these regions, the case fatality rate for childhood
pneumonia associated with TB is high, ranging from 4
to 21% [10], with younger age, malnutrition and HIV in-
fection increasing the risk of death [12, 13]. However,
the diagnosis of TB in children with severe pneumonia
remains low. Indeed, the current WHO standard of care
(SOC) for young children with pneumonia considers a
diagnosis of TB only if the child has a history of pro-
longed symptoms or fails to respond to antibiotics [14].
Therefore, many children with TB-associated severe
pneumonia are currently missed or diagnosed too late,
which is likely to affect their outcome.
In 2013, WHO updated its policy to include Xpert
MTB/RIF (Cepheid, USA) as the initial test for the diagno-
sis of TB in children, based on a meta-analysis showing a
pooled sensitivity and specificity of Xpert MTB/RIF per-
formed on gastric lavages of 66% (95% confidence interval
51–81) and 98% (95% confidence interval 96–99), respect-
ively, when compared with culture [15, 16]. Although data
on the performance of Xpert MTB/RIF in children with
pneumonia are limited, in Bangladesh, sensitivity on gas-
tric aspirates or sputum samples compared to culture in
this group was equivalent to that reported in other studies
[17]. The next-generation of Xpert MTB/RIF assay, Xpert
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MTB/RIF Ultra (Ultra), has a lower detection threshold
(similar to culture), which is expected to improve the diag-
nosis of children with paucibacillary TB [18, 19].
Previous studies in Africa and Asia have shown that
alternative specimen collection methods such as naso-
pharyngeal aspirates (NPA) and stool samples are easier
to implement, and are better tolerated in young and sick
children [20–24]. These methods do not require a child
to fast, as mandatory for gastric aspirates, and are more
suitable than induced sputum in children with severe re-
spiratory deficits [25]. Recent studies have shown similar
sensitivity of Xpert MTB/RIF on the combination of one
stool and one NPA as compared to two induced sputum
or two gastric aspirates [20, 26].
We therefore propose a diagnostic trial to assess the im-
pact on mortality of adding the systematic early detection
of TB using Ultra performed on NPA and stool samples
to the WHO SOC for children with severe pneumonia,
followed by immediate initiation of anti-TB treatment in
children testing positive on any of the samples. Our hy-
pothesis is that in high TB burden countries, testing young
children with severe pneumonia for TB and starting those
who test positive on anti-TB treatment on the day of pres-
entation, could reduce all-cause mortality through reduc-
tion of mortality attributed to TB.
Methods
Aim
The primary objective of the TB-Speed Pneumonia trial
is to evaluate the impact on all-cause mortality at 12
weeks post inclusion of adding systematic early detection
of TB with Ultra, performed on one NPA and one stool
sample in young children with severe pneumonia,
followed by immediate anti-TB treatment initiation in
children with a positive Ultra result, in high TB inci-
dence countries, as compared to the WHO SOC alone.
The study only includes children with community-
acquired pneumonia, excluding children already hospi-
talized who have developed a nosocomial pneumonia.
Secondary objectives will assess the impact of the sys-
tematic TB detection on TB case detection, time to TB
treatment initiation, inpatient mortality, duration of initial
hospitalization and hospital readmission rate, and will as-
sess the feasibility and acceptability of the intervention.
Trial design
TB-Speed Pneumonia is an international, cluster-randomised
trial with a stepped wedge design. Stepped wedge trials are
randomised controlled trial in which clusters successively
switch from control to intervention, in an order randomly
assigned, until all clusters are eventually exposed to the inter-
vention (Table 1). In our study, all hospitals (clusters) start
by implementing the WHO SOC for severe pneumonia
(control arm) and are randomly allocated a time at which
they will transition to implementing the intervention. De-
pending on the time at which they are enrolled in the study,
children pertain either - and exclusively – to the control
arm, or the TB-Speed intervention arm.
Study settings
The impact of this innovative approach may vary with
TB incidence as well as geographical and seasonal vari-
ability that can affect the prevalence and aetiology of
pneumonia in young children. To provide a better basis
for the generalisability of results, the trial takes place in
six countries. These include high and very high tubercu-
losis incidence countries with different epidemiological
and environmental backgrounds, in Sub-Saharan Africa
(Cameroon, Cote d’Ivoire, Mozambique, Uganda, and
Zambia) and South East Asia (Cambodia) (Table 2). The
trial is implemented in 15 national or regional reference
hospitals with previous research experience.
Randomisation
Randomisation is stratified by the estimated country TB
incidence rate, classified as either high (100 to < 300/
100,000 patients-years; Cameroon, Côte d’Ivoire and
Uganda) or very high (≥ 300/100,000 patients-years;
Cambodia, Mozambique and Zambia) [9] (Table 1).
Within these strata, a computer-generated random se-
quence will determine the order in which hospitals move
from control to intervention. The statistician of the
international coordination team, based at University of
Bordeaux, will prepare the randomization sequence be-
fore the start of the trial.
The time when a new cluster receives the intervention
is called a step. In the TB-Speed Pneumonia study, the
period between two successive steps is 5 weeks (Table 1).
The international coordination team and country re-
search teams are blinded to the randomisation order.
The international coordination team however is in-
formed 10 weeks in advance (i.e. two periods) of the next
site to switch, while study sites are notified 5 weeks prior
to their crossover date to initiate program planning.
Study population
Any child younger than five years presenting with signs and
symptoms of presumptive severe pneumonia to outpatient,
emergency units, intensive care unit, or paediatric depart-
ments of the selected hospitals is screened for eligibility for
the trial as soon as possible. Eligibility to participate includes
the following criteria: (1) aged 2 to 59months, (2) newly hos-
pitalized for WHO-defined severe pneumonia (Table 3), (3)
informed consent signed by parent/guardian. Ongoing TB
treatment or history of intake of anti-TB drugs in the last 6
months is the only exclusion criterion.
Vessière et al. BMC Pediatrics          (2021) 21:136 Page 3 of 12
Trial intervention strategy
The WHO standard of care for children with severe
pneumonia
All children admitted in the hospital and presenting with
WHO-defined severe pneumonia are immediately man-
aged as part of routine care per the WHO SOC for chil-
dren with severe pneumonia (Table 4).
As recommended by the WHO for TB assessment in
the context of the SOC, if the child presents with persist-
ent cough and fever for more than two weeks, and signs
of pneumonia after adequate antibiotic treatment, s/he is
evaluated for TB using routine procedures. Xpert or Ultra,
depending on local availability, can be used in children
with clinical suspicion of TB (chronic symptoms, failure







01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
High 01 CT INT INT INT INT INT INT INT INT INT INT INT INT INT INT INT
Very high 02 CT CT INT INT INT INT INT INT INT INT INT INT INT INT INT INT
High 03 CT CT CT INT INT INT INT INT INT INT INT INT INT INT INT INT
Very high 04 CT CT CT CT INT INT INT INT INT INT INT INT INT INT INT INT
High 05 CT CT CT CT CT INT INT INT INT INT INT INT INT INT INT INT
Very high 06 CT CT CT CT CT CT INT INT INT INT INT INT INT INT INT INT
High 07 CT CT CT CT CT CT CT INT INT INT INT INT INT INT INT INT
Very high 08 CT CT CT CT CT CT CT CT INT INT INT INT INT INT INT INT
High 09 CT CT CT CT CT CT CT CT CT INT INT INT INT INT INT INT
Very high 10 CT CT CT CT CT CT CT CT CT CT INT INT INT INT INT INT
High 11 CT CT CT CT CT CT CT CT CT CT CT INT INT INT INT INT
Very high 12 CT CT CT CT CT CT CT CT CT CT CT CT INT INT INT INT
High 13 CT CT CT CT CT CT CT CT CT CT CT CT CT INT INT INT
Very high 14 CT CT CT CT CT CT CT CT CT CT CT CT CT CT INT INT
High 15 CT CT CT CT CT CT CT CT CT CT CT CT CT CT CT INT
CT control (WHO recommended standard of care for children with severe pneumonia), INT TB-Speed intervention (systematic early detection of tuberculosis in
addition to the WHO recommended standard of care for children with severe pneumonia)
Table 2 Implementing sites
Region Country TB incidence rate /100,000 population Number of sites Hospitals, City
Western Africa Côte d’Ivoire High (< 300) 148 3 Yopougon UTH, Abidjan
Treichville UTH, Abidjan
Cocody UTH, Abidjan
Central Africa Cameroon 194 2 Chantal Biya Foundation, Yaoundé
District Hospital Biyem Assi, Yaoundé
Eastern Africa Uganda 201 3 Mulago National Referral Hospital, Kampala
Holy Innocents Childrens’ Hospital, Mbarara
Regional Reference Hospital, Jinja
Southern Africa Mozambique Very high (≥300) 551 2 Central Hospital, Maputo
Jose Macamo General Hospital, Maputo
Zambia 361 2 UTH, Lusaka
Arthur Davidson Children Hospital, Ndola
South East Asia Cambodia 326 3 Referral Hospital, Kampong Cham
Referral Hospital, Takeo
National Pediatric Hospital, Phnom Penh
UTH University Teaching Hospital. Data source: WHO Global TB Report 2019 [1]
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to respond to antibiotic treatment or TB exposure) ac-
cording to the clinician’s judgement. This can be done
using the standard sample collection methods usually im-
plemented at the inpatient ward.
The TB-Speed intervention
The intervention consists of the WHO SOC for children
with severe pneumonia plus the trial intervention con-
sisting of systematic, rapid detection of TB on the day of
hospital admission using the Ultra assay performed on 1
NPA and 1 stool sample. Ultra testing on NPA is per-
formed immediately, either at the hospital laboratory
with the standard GeneXpert device, or undertaken in
the ward or in a side-laboratory next to the ward using a
one-module GeneXpert device (G1 Edge®, Cepheid). The
sample flow has been organised in order to reduce turn-
around time for results to 3 h. Ultra testing on stool,
which requires prior processing, is performed at the hos-
pital laboratory. Drugs are available at the inpatient level
to enable immediate initiation of TB treatment, as soon
as a positive Ultra result is released.
Implementation procedure
Aggregated data on severe pneumonia management were
collected in all hospitals two months prior to the start of
the study to document routine practices for the SOC for
severe pneumonia in children (number of hospitalizations,
inpatient mortality, antibiotic use, access to oxygen ther-
apy and other supportive care). Adherence to the WHO
SOC for severe pneumonia was reinforced by initial study
training and is monitored throughout the study imple-
mentation. The study provided equipment for oxygen
therapy (oxygen concentrators) where needed, and pulse
oximeters. It is expected that the provision of equipment
for oxygen therapy and training on pneumonia case man-
agement in children will reduce the variation in character-
istics and practices between sites.
Study visits and assessments
After written informed consent is obtained from par-
ent(s)/guardian(s) by the study clinician or study nurse,
the baseline visit includes a complete clinical evaluation,
a digitalized chest X-ray (CXR), HIV and malaria testing,
and a complete blood count. For children in the inter-
vention arm, initial bacteriological specimen collection is
done as soon as possible and within 24 h of hospital ad-
mission, including one NPA collected by the nurse on
the day of admission, and one stool sample collected as
soon as the child is able to produce stool. Additionally,
blood samples and leftovers from NPA and stool are col-
lected for future biomarkers studies in children for
whom parent(s)/guardian(s) give their consent for bio-
banking. Data about routine care as well as additional
Table 3 WHO criteria for severe pneumonia
MANDATORY PLUS ≥ 1 of the following
Cough OR difficulty in breathing Peripheral oxygen saturation < 90%
Central cyanosis
Severe respiratory distress Grunting
Nasal flaring
Very severe chest indrawing
Signs of pneumonia (tachypnea OR chest indrawing)
AND at least one danger signs (a to f)
(a) Inability to breastfeed or drink
(b) Persistent vomiting
(c) Lethargy or reduced level of consciousness
(d) Convulsions
(e) Stridor in calm child
(f) Severe malnutrition
Table 4 The WHO standard of care for young children with
severe pneumonia
Care Conditions
Antibiotics Broad spectrum intravenous antibiotics
Oxygen therapy If oxygen saturation < 90% or signs of hypoxia
Additional supportive
care
Airway management, fever treatment,
bronchodilators or steroids, fluids and
nutritional support (including breastfeeding or




Chest X-ray If possible, for children with severe pneumonia
not responding to treatment or complications
or unclear diagnosis or associated with HIV
Monitoring By a nurse at least every 3 h and by a doctor at
least twice a day
Follow up If possible, 2 weeks after discharge, to check
the child’s nutrition
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study strategies are collected. All children are
followed up for a total duration of 12 weeks, with
four systematic protocol visits planned at day 3 (and/
or at hospital discharge), 2 weeks after discharge (as
recommended by the WHO SOC), and 12 weeks after
recruitment. Each follow-up visit comprises a clinical
evaluation, and collection of medical history since the
last visit, an evaluation of adherence to TB treatment
if initiated, and TB drug prescription and dispensation
to cover the time until the next visit (Table 5). Par-
ent(s)/guardian(s) are invited to bring their child back
to the hospital in case of new symptoms for an un-
scheduled (extra) visit. During the final visit at 12
weeks, a second digital CXR is performed, as well as
an assessment of TB disease evolution and TB treat-
ment outcome in those diagnosed with TB (improve-
ment, treatment failure, death, or lost to follow-up).
Tolerability and acceptability of the intervention
Assessment of the tolerability and acceptability of NPA
and stool specimen collection procedures will be under-
taken in a subset of children. Tolerability is defined by
the child’s perceived level of discomfort/distress/pain as
assessed by the child him/herself, the parents/guardians
and the nurses using the Wong-Baker Face scale, the
Visual Analog Scale, and the FLACC (Face Legs Activity
Cry Consolability) behavioural scale, respectively.
Nurses’ and parents’ acceptability regarding the whole
sampling and testing strategy will be evaluated using
both quantitative (self-reported questionnaire) and quali-
tative methods (semi-structured interviews).
Safety assessment
Occurrence of Adverse Events (AEs) is monitored at each
visit by study nurses and clinicians for children receiving
the TB-Speed intervention. Expected AEs occurring from
NPA collection include, by decreasing order of frequency:
cough, nausea, local trauma/nose bleeding, sneezing,
vomiting, and in rare cases dyspnoea/low oxygen satura-
tions and bradycardia < 60/bpm [33]. No AEs are expected
from stool sample collection. Since this is a diagnostic trial
without investigational medicinal product, and very low
expected risk of AEs linked to the intervention, there is no
systematic notification of severe AEs (SAEs) to the spon-
sor with the exception of: 1) death; 2) grade 4 clinical AEs
(excluding asymptomatic biological grade 4 AEs); or 3)
SAEs related to NPA collection. Grading will be done
using the 2017 Division of AIDS Table for Grading the Se-
verity of Adult and Pediatric Adverse Events [27].
Endpoints
Primary study endpoint and measure
The primary endpoint is all-cause mortality 12 weeks
after recruitment. Mortality due to severe pneumonia
(related or not to TB) is expected to occur early. We ex-
pect that a 12-week period is long enough to assess im-
pact on mortality of TB treatment empirically started in
children with poor clinical progress during the first
weeks of follow-up. If the children are not brought to
the Week 12 visit, parents will be contacted, and home
visits will be organized in order to collect the vital status
of the child.
Secondary study endpoints and measures
Several secondary endpoints will further compare the
intervention and control arms and document the feasi-
bility and acceptability of the intervention (Table 6). Of
note, some endpoints are collected all along the trial for
process monitoring and assessment of the feasibility of
the TB-Speed intervention. Among others, they include
the proportion of children with NPA and stool samples
collected as per protocol and the time to sample collec-
tion and Xpert result after collection.
Data analysis
We will perform final data analysis to answer the objec-
tives at the end of the study after data review and data-
base closure. At the request of the trial Independent
Data Monitoring Committee (IDMC), an interim ana-
lysis on safety and feasibility data is planned at the point
when all children enrolled during the first 9 months of
the study have been followed for 12 weeks; there are no
stopping rules planned and no formal statistical test will
be used. We will conduct a descriptive analysis of the
endpoints and other measured variables and characteris-
tics (Table 6). Quantitative variables will be summarized
using means, standard deviation, median and interquar-
tile range. Categorical variable will be analysed using fre-
quencies and proportions.
The analysis of the primary endpoint will be per-
formed following an intention-to-treat principle. Pat-
terns of missing values will be analysed but no
imputation will be done. As the literature regarding stat-
istical analysis of stepped wedge designs is constantly
growing, we will follow the recommendations of Hem-
ming and colleagues [28], using the Hussey and Hughes
model for the primary analysis [29]. Thus, we will used
generalised linear mixed models with logit link and bin-
ary distribution. We will model individual binary re-
sponse (vital status) with condition (control vs
intervention) and time-period as fixed effects and sites
as random effects to adjust for clustering of children.
Sensitivity analyses will be performed to control for 1)
important prognostic factors such as age, malnutrition,
HIV infection, severity criteria measured at recruitment,
2) seasonality which could be different in different coun-
tries and, 3) different model specifications to better ad-
just secular trends and cluster heterogeneity [28]. These
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model specifications are developed and detailed in a stat-
istical analysis plan that will be validated by the IDMC
before performing the analysis. All results will be re-
ported as estimates of effect (odds ratios for binary vari-
ables) and corresponding 95% confidence intervals. We
will conclude that the intervention is better than the
control if the mortality odds ratio is statistically lower
than 1 (p < 0.05).
All analyses will be performed using R (version 3.6.0
or higher) and findings will be reported as per the CON-
SORT extension for reporting of stepped-wedge cluster-
randomized trials [30].
Power and sample size
Sample size calculations were performed based on sev-
eral assumptions. (1) The expected proportion of TB
cases in children with pneumonia would be 15 and 24%,
in high and very high incidence settings, respectively,
with a proportion of 33% of culture confirmed cases
among TB cases overall (2). In the context of our inter-
vention, Ultra could detect the majority of confirmed TB
cases, versus a hypothesized TB detection rate of 25% in
routine conditions. (3) The intervention would raise
awareness about TB in site clinicians and would lead to
an increase in detection rate from 15 to 50% between
the control and the intervention arm. (4) We estimate
Table 5 Study assessments and specimen collection
Inclusion
(Day 0)
Day 3 Discharge 2Weeks Post-Discharge (Extra visit)i Week 12
STANDARD OF CARE (control and intervention arm)
WHO Standard of Carea,b X X X X (X) X
TB clinical assessmentc (X) (X) (X) (X) (X)
TB treatment if neededb, d (X) (X) (X) (X) (X)
TB-SPEED INTERVENTION (intervention arm only)
Nasopharyngeal aspirate X
Stool sample X
Xpert MTB/RIF Ultra X
Immediate TB treatment initiation if positive Ultra testb X
Biobank: NPA and stool leftovers X
Tolerability and acceptability of NPA collectionh X
ADDITIONAL STUDY ASSESSMENT AND PROCEDURES (control and intervention arm)
Eligibility screening X
Clinical evaluatione X X X X (X) X
Medical history X X X X (X) X
Digital chest X-Ray X (X) X
Safety assessment X X X X (X) X
TB drug adherence assessment (X) (X) (X) (X)
TB treatment response X X
HIV testf X
Malaria test X
Complete blood count X
Biobank: plasma, whole bloodg X
WHO World Health Organization, TB tuberculosis, NPA nasopharyngeal aspirate
aSee Table 4
bAccording to national treatment guidelines based on WHO recommendations
cIn children with a clinical suspicion of TB (chronic symptoms, failure to respond to antibiotic treatment or TB exposure), TB will be evaluated using routine
procedures. This can include Xpert MTB/RIF or Ultra (depending on local availability) on standard bacteriological samples as usually implemented at the ward
dIn the intervention arm, TB treatment will be initiated immediately in case of a positive Ultra result. In both arms, TB treatment could be initiated in case of a
strong clinical suspicion
eContent of clinical evaluation varies with the visit; includes TB exposure and symptoms assessment at inclusion
fPerformed if not available in the patient medical chart. In Côte d’Ivoire, should be discriminant for HIV 1 and 2
gIn children < 18 months weighing < 5 kg, or presenting with signs of severe anaemia (conjunctival or palmar pallor): plasma sample for biobank will not be
collected. Overall, volume of blood draw must not exceed 3 ml/kg/visit and 7 ml/kg/6 weeks
hIn a subset of children only
iAn extra TB visit will be performed if the child presents with signs and symptoms in favour of a presumptive TB
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that in the control arm the overall mortality will reach
15%, in line with mortality associated to severe pneumo-
nia in previous studies, and that the intervention would
therefore lead to a 30% reduction in the overall mortality
rate (10.5%).
According to these assumptions, the sample size for
an individual randomized trial would be 1730 children.
For financial and logistical reasons, we retained an ICC
value of 0.005, corresponding to a design effect of 2.16
[31]. Using the estimated mortality of 15% in the control
arm, an expected reduction in mortality in the experi-
mental arm of 30%, an alpha of 0.05, a power of 80%, an
ICC of 0.005 and 1% of incomplete data, the corre-
sponding sample sizes would be 3780 children. This
sample size randomised across the two strategies, in 15
hospitals over 16 periods, resulted in a mean of 15.8
children enrolled per hospital per time period (or 252
children per hospital for the entire study), with no re-
striction if included numbers exceed this target.
Data management and confidentiality
Patient data will be recorded into an electronic case re-
port form by study nurses through single data entry on
tablets using the REDCap application. All electronic data
will be kept on a password-protected, secured server
hosted at the University of Bordeaux, accessible only to
researchers involved in this trial. Each trial participant
will be assigned a unique study identification code.
Table 6 Secondary endpoints
Endpoints Measures Time of measurement
Secondary endpoints considered for a comparison between arms
TB diagnosis based on the clinician’s
judgement
# of children diagnosed with TB based on the clinician’s
judgement
Any time during the follow-
up
TB treatment initiation Proportion of children diagnosed with TB AND who with at least
one TB treatment recorded
Any time during the follow-
up
Time to TB treatment initiation Date/Time of the 1st TB treatment – Date/Time of TB diagnosis (in
hours)
Any time during the follow-
up
Duration of TB treatment at end of trial Number of days between date of TB treatment initiation and date
of TB treatment end
Any time during the follow-
up (week 12 or early
termination)
Inpatient deaths # of children who died after inclusion and before hospital
discharge
Before discharge
Duration of initial hospitalization Date of the 1st recorded discharge – Date of the 1st recorded
admission (in days)
At the first discharge
Readmission following discharge # of admission occurring after the 1st discharge Any time during the follow-
up
Weight gain Proportion of weight gain at 12 weeks (as compared to body
weight at inclusion)
At 12 weeks
Cost effectiveness Incremental cost-effectiveness ratio (ICER) of intervention com-
pared with WHO SOC, measured in cost per DALY averted
Lifetime, based on differences
in mortality up to 12 weeks
Secondary endpoints assessed in the intervention group only
TB detection by NPA testing Proportion of NPA with positive TB detection using Ultra After 1st visit
TB detection by Stool testing Proportion of stool samples with positive TB detection using Ultra After 1st visit
TB detection by NPA and Stool testing Proportion of samples (NPA and/or stool) with positive TB
detection using Ultra
After 1st visit
Turnaround time between NPA collection
and result of Ultra
Date/Time of Ultra results – Date/Time of NPA collection After 1st visit
Turnaround time between stool sample
collection and result of Ultra
Date/Time of Ultra results – Date/Time of stool sample collection After 1st visit
NPA collected as per protocol Proportion of children with NPA collected as per protocol At 1st visit
Stool samples collected as per protocol Proportion of children with stool samples collected as per protocol At 1st visit
Safety: adverse events (AEs) during NPA
collection
Number of adverse events collected by study nurses during NPA
collection including as vomiting, nose bleeding, low oxygen
saturation
Any time during the follow-
up
Tolerability: discomfort/pain/distress
experienced by the child during NPA
collection procedure
Assessed by the child him/herself (Wong-Baker face scale), by the
parents (visual analog scale), by the nurses (FLACC behavioural
scale)
At NPA collection time
TB tuberculosis, NPA nasopharyngeal aspirate
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Oversight
The trial is coordinated primarily by the international
Central Coordination Unit at University of Bordeaux,
France and is overseen by the Trial Steering Committee.
A Scientific Advisory Board (SAB) provides advice on the
relevance and validity of the project design and implemen-
tation, monitors progress and ensures scientific and
ethical integrity of the project. An IDMC acts as a con-
sultative board for the SAB and the sponsor. It has access
to overall safety and efficacy data, as well as to any infor-
mation justifying continuation or discontinuation of the
trial. However, the IDMC will not apply stopping rules
and interim analyses as per standard clinical trials since
the stepped wedge design does not allow for it.
Sub-studies
Cost-effectiveness study
We hypothesise that benefits in terms of survival and in-
creased Disability-Adjusted Life Years (DALYs) over a life-
time horizon will justify extra costs incurred by systematic
Ultra testing in children with severe pneumonia. A math-
ematical model will be developed to project health eco-
nomic outcomes, including TB cases and mortality in
children with severe pneumonia. Cost-effectiveness ana-
lysis will be from the health payer perspective and only
direct healthcare costs will be included. Budget impact
analysis will be conducted to evaluate the expected costs
of implementing the TB-Speed approach on healthcare
budget at 2- and 5-year horizons in the countries partici-
pating in the project.
Biomarkers studies
Baseline samples, including NPA and stool leftovers,
whole blood and plasma samples collected at inclu-
sion, will be frozen and stored at the country clinical
trial unit laboratory. The trial provides a unique op-
portunity to investigate a number of TB biomarkers,
which could discriminate active disease from latent
TB infection as well as TB from non-TB pneumonia
using transcriptomic approaches. It also permits the
study of the molecular epidemiology of Mycobacter-
ium tuberculosis, and further characterisation of the
proteomic, metabolic and immunologic profiles of
children presenting with signs of severe pneumonia,
with or without TB [32–36]. Biological samples will
be retained for 10 years after study completion, unless
there are objections expressed by parent(s)/
guardian(s).
Trial status
Recruitment to the trial started in March 2019. Recruit-
ment will continue until September 2020, with the last
visit of the last participant in December 2020. The
current protocol is Version 2.0 dated November 22nd,
2019.
Discussion
TB-Speed Pneumonia is a pragmatic diagnostic trial with a
stepped-wedge cluster-randomised design, and a stratified
randomisation. The stepped wedge cluster-randomised de-
sign enables evaluation of the study hypothesis using a prag-
matic and operational approach, i.e. for an intervention
which remains to be tested in a real-world setting. To our
knowledge, this is the first time a stepped wedge trial has
been implemented at the international level [37–39].
Strengths and challenges of the stepped-wedge design
The stepped wedge design is particularly relevant where
it is predicted that the intervention will ultimately do
more good than harm, as is the case for our interven-
tion, but where there is uncertainty as to its effectiveness
and its safety in a specific setting and population [40].
The choice of the stepped wedge design was also based
on our hypothesis that the intervention would raise TB
awareness among clinicians and may lead to more em-
pirical TB treatment initiated in the intervention arm as
compared to the control arm, thus benefitting all chil-
dren hospitalized, and impacting beyond the research
settings. Since clusters are expected to remain until the
study ends, they will all eventually implement the inter-
vention. The stepped-wedge design is therefore particu-
larly adapted to capture such effects. From a logistical
point of view, a phased roll-out of the intervention is
easier to implement in the context of an international
multicentre study. Randomisation per hospital is also ad-
vantageous due to the difficulty at health facility level of
randomising children individually to one of the two
strategies, additionally minimising contamination be-
tween the two arms.
A major limitation of stepped wedge designs is that
blinding of the study team to the intervention is not pos-
sible. However, since the primary trial endpoint (mortal-
ity at 12 weeks) is not subjective, there is no risk of
ascertainment bias. As the intervention relates to the
management of children upon hospital admission,
outcomes are estimated only from individuals with no
prior exposure to the control, thus avoiding carryover
(residual) effect [41]. Moreover, in order to guarantee
that children benefit from the same quality of care
across study sites, adherence to WHO SOC for severe
pneumonia will be monitored throughout the study
implementation.
Challenges to this design include the need for re-
peated training activities and increasing workload for
coordination teams as more clusters start the inter-
vention. Although all hospitals will finally implement
the intervention, some of them will remain in the
Vessière et al. BMC Pediatrics          (2021) 21:136 Page 9 of 12
control arm for a long time, requiring continuous en-
gagement to avoid drop-out and demotivation. In this
study, the number of participants is not capped,
which can be challenging for resource planning. Since
all study sites are expected to start on the same day,
as per the stepped wedge design, any delay in open-
ing a site impacts all others.
In this multi-country study with different epidemio-
logical and environmental backgrounds, one can expect
to face variability in the number of recruitments across
clusters and time-periods (seasonal effect). Although the
impact of unequal cluster size on statistical precision has
been previously investigated, further research is needed
to apply previous results to binary outcomes and to con-
sider size variation across clusters and time-periods [42].
Conclusion
TB-Speed Pneumonia will test an innovative interven-
tion to diagnose TB in children with severe pneumonia,
in a pragmatic cluster randomised stepped-wedge trial.
In addition to testing the main hypothesis that molecular
detection and early treatment will reduce TB mortality
in children, the strength of such pragmatic research is
that it helps to provide some evidence regarding the
feasibility of the intervention as part of routine care. A
systematic review, commissioned by WHO in 2019, pro-
vided additional evidence on the use of Xpert MTB/RIF
and Ultra as initial diagnostic tests for TB in children,
specifically in NPA and stool specimens. The sensitivity
of Xpert MTB/RIF (as compared to liquid culture of a
respiratory specimen) was of 46 and 61% on NPA and
stool specimens respectively, as compared to 65% on
sputum and 73% on gastric specimens, and the sensitiv-
ity of Ultra was of 46 and 73% on NPA and sputum, re-
spectively. The specificity for all samples was above 98%
(97% for Ultra) [43].
Should this intervention be successful, safe and well
tolerated, it could be systematically implemented in
order to increase TB diagnosis in children with severe
pneumonia and reduce childhood mortality due to TB.
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